StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a report released on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Aptose Biosciences Stock Performance
APTO stock opened at $0.40 on Friday. Aptose Biosciences has a one year low of $0.33 and a one year high of $3.32. The stock has a market capitalization of $7.17 million, a PE ratio of -0.06 and a beta of 1.26. The company has a fifty day moving average of $0.40 and a 200-day moving average of $0.74.
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.15.
Hedge Funds Weigh In On Aptose Biosciences
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Articles
- Five stocks we like better than Aptose Biosciences
- Why Invest in 5G? How to Invest in 5G Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Energy and Oil Stocks Explained
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Most active stocks: Dollar volume vs share volume
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.